Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Develops Formal Procedure To Refer Misleading Communications To SEC

This article was originally published in The Pink Sheet Daily

Executive Summary

Associate Commissioner for Regulatory Affairs John Taylor will serve as the liaison between the agencies. FDA will provide "blanket" authorization to certain staff to share non-public information with SEC.

You may also be interested in...



The Omniscient Regulator: QRxPharma’s Unusual Take on FDA and Investor Calls

Investor calls routinely begin with a disclaimer that the call is being recorded. They don’t usually include a warning that “FDA is monitoring the call.” But that is how QRxPharma began a discussion of a bad news event for its MoxDuo application.

FDA Refers Several Full Disclosure, Insider Trading Violations To SEC

More than half a dozen FDA-referred cases are under investigation at the Securities & Exchange Commission, official says. FDA is “struggling” to provide SEC with full disclosure support without jeopardizing confidential proprietary information. Three of the six cases also involve insider trading.

FDA Refers Several Full Disclosure, Insider Trading Violations To SEC

More than half a dozen FDA-referred cases are under investigation at the Securities & Exchange Commission, official says. FDA is “struggling” to provide SEC with full disclosure support without jeopardizing confidential proprietary information. Three of the six cases also involve insider trading.

Related Content

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel